TrialCancer medicine2020

Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results.

Thomas Zilli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.